Se o paciente apresenta um quadro gripal de causa desconhecida, inicie o oseltamivir 75 mg 2xd em todos os pacientes adultos com função renal normal (interromper o uso se a PCR para influenza A/B for negativa ou houver baixa suspeita). Ajustar a dose para pacientes pe- diátricos ou com insuficiência renal.
Considerações para o tratamento empírico da pneumonia bacteriana:
Ceftriaxona 1g 2xd + azitromicina 500 mg 1xd + vancomicina se fatores de risco para MRSA por 5 dias, ou mais, guiado pelo estado clínico e pela microbiologia.
Dos estudos realizados até o momento, a procalcitonina permanece baixa nos pri- meiros 7 a 10 dias de infecção e pode aumentar mais tarde, mesmo sem superinfecção bacteriana.
Referências
1. Peeri NC, Shrestha N, Rahman S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International Journal of Epidemiology. 2020. DOI: 10.1093/IJE/DYAA033.
2. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavi- rus of probable bat origin. Nature. 2020;579(7798):270-3.
3. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. 4. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SAR- S-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Mar 17. doi: 10.1056/NE- JMc2004973.
5. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.
6. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33.
7. National Health Commission and National Administrative O ce of Chinese Traditional Me- dicine: National Recommendations for Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (6th edition). Available at: http://www.nhc.gov.cn/ yzygj/s7653p/202002/8334a- 8326dd94d329df351d- 7da8aefc2.shtml. Accessed February 18, 2020.
8. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
9. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020. doi: 10.1016/j.apsb.2020.02.008.
10. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences. 2020;63(3):457-60.
11. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology. 2020. doi: 10.1038/s41564-020-0688-y.
12. Lu R, Zhao X, Li J, Niu P, et al. Genomic characterisation and epidemiology of 2019 no- vel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-74.
13. Hoffman M, Kliene-Weber H, Krüger N, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1-10. 14. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epide-
miological characteristics of an outbreak of 2019 novel Coronavirus diseases (COVID-19) − China, 2020. China CDC Wkly. 2020;2:113-22.
15. Huang C, WangY, Li X, et al. Clinical features of patients infected with 2019 novel corona- virus in Wuhan, China. Lancet. 2020;395:497-506.
16. Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032.
17. Yang Z, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS- CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 Feb 24. doi: 10.1016/S2213-2600(20)30079-5.
18. https://www.entnet.org/content/coronavirus-disease-2019-resources (Accessed on March 23, 2020).
19. Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiang- su Province: a multicenter descriptive study. Clin Infect Dis. 2020 Feb 29. pii: ciaa199. doi: 10.1093/cid/ciaa199.
20. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
21. Wit ED, Doremalen NV, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-34.
22. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 ex- pression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618-25. 23. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019
novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/ jama.2020.1585.
24. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020 Mar 16. pii: ehaa190. doi: 10.1093/eurheartj/ ehaa190.
25. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25. doi: 10.1001/jamacar- dio.2020.0950.
26. Chau TN, Lee KC, Yao H, et al. SARS-associated viral hepatitis caused by a novel coronavi- rus: report of three cases. Hepatology. 2004;39:302-10.
27. Alsaad KO, Hajeer AH, Al Balwi M, et al. Histopathology of Middle East respiratory syn- drome coronovirus (MERS-CoV) infection-clinicopathological and ultrastructural study. Histopathology. 2018;72:516-24.
28. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumo- nia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; published online Feb 24. doi: 10.1016/S1473-3099(20)30086-4.
29. Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; published online Feb 19. doi: 10.1136/bmj.m606.
30. Pan L, Mu M, Ren HG, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastro- enterol. 2020.
31. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020; published online Feb 19. doi: 10.1016/S2468-1253(20)30048-0.
32. Alsaad KO, Hajeer AH, Al Balwi M, et al. Histopathology of Middle East respiratory syn- drome coronovirus (MERS-CoV) infection-clinicopathological and ultrastructural study. Histopathology. 2018;72:516-24.
33. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver da- mage after 2019-nCoV infection. bioRxiv 2020; published online Feb 4. Available at: https:// doi.org/10.1101/2020.02.03.931766 (preprint).
34. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respi- ratory distress syndrome. Lancet Respir Med. 2020; published online Feb 18. doi: 10.1016/ S2213-2600(20)30076-X.
35. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/angiotensin 1-7 axis of the renin -angiotensin system in heart failure. Circ Res. 2016;118:1313-26.
36. Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122:717-28. 37. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhi-
bitors in patients with Covid-19. N Engl J Med. 2020 Mar 30. doi: 10.1056/NEJMsr2005760. 38. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angioten-
sin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-43.
39. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-7.
40. Serfozo P, Wysocki J, Gulua G, et al. Ang II (angiotensin II) conversion to angiotensin (1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-con- verting enzyme 2)-independent. Hypertension. 2020;75:173-82.
41. Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS- CoV-2 spike glycoprotein. Cell. Mar 6, 2020. doi: 10.1016/j.cell.2020.02.058.
42. Clerkin KJFJ, Raikhelkar J, Sayer G, et al. Coronavirus disease 2019 (COVID-19) and cardio- vascular disease. Circulation. Mar 21, 2020. doi: 10.1161/CIRCULATIONAHA.120.046941. 43. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the pre-
44. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the func- tional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7.
45. Xudong X, Chen J, Wang X, et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166-71.
46. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhi- bition and angiotensin II receptor blockers on cardiac angiotensin-converting rnzyme 2. Circulation. 2005;111(20):2605-10.
47. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of angiotensin- converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006;48(4):572-8.
48. Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzy- me 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970-6.
49. Soler MJ, Ye M, Wysocki J, et al. Localization of ACE2 in the renal vasculature: amplifi- cation by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296(2):F398-405.
50. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26(4):369-75.
51. Burchill LJ, Velkoska E, Dean RG, et al. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implica- tions for future therapeutic directions. Clin Sci (Lond). 2012;123(11):649-58.
52. Ramchand J, Patel SK, Srivastava PM, et al. Elevated plasma angiotensin converting enzy- me 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One. 2018;13(6):e0198144.
53. Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 2 in hyper- tensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28(1):15-21.
54. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015;47(4):693-705.
55. Deshotels MR, Xia H, Sriramula S, et al. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor- dependent mechanism. Hypertension. 2014;64(6):1368-75.
56. Henry C, Zaizafoun M, Stock E, et al. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018;31(4):419-23.
57. Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014;4:7027.
58. https://dgs-urgent.sante.gouv.fr/dgsurgent/inter/detailsMessageBuilder.do?id=30500&- cmd=visualiserMessage. Accessed on March 19, 2020).
59. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086.
60. Updated: WHO now doesn’t recommend avoiding ibuprofen for COVID-19 symptoms. Science Alert. 2020. Available at: https://www.sciencealert.com/who-recommends-to-a- void-taking-ibuprofen-for-covid-19-symptoms. Accessed on March 19, 2020.
61. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflamató- rias for COVID-19. Available at: https://www.ema.europa.eu/en/news/ema-gives-advice-u- se-non-steroidal-anti-inflammatories-covid-19. Accessed on March 19, 2020.
62. Wang W, Xu Y, Gao R, et al. Detector of SARS-CoV-2 in different types of clinical espécimen. JAMA. 2020 Mar 11. doi: 10.1001/jama.2020.3786.
63 Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.
64. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
65. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396).
66. Colson P, Rolain JM, Lagier JC, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Mar 4:105932. doi: 10.1016/j.ijan- timicag.2020.105932.
67. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing de- sign of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Co- ronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi: 10.1093/cid/ciaa237. 68. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent effi-
cacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.
69. Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949.
70. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and sa- fety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10. pii: S0883- 9441(20)30390-7.
71. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.03.22.20040758; doi: https://doi.org/10. 1101/2020.03.22.20040758.
72. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome co- ronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58:4875-84. 73. Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b
improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212:1904-13.
74. Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252-6.
75. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with Severe Covid-19. N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa2001282.
76. Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009;43:29798-808.
77. Belardo G, La Frazia S, Cenciarelli O, et al. Nitazoxanide, a novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors. 49th Infectious Disease Society of America Annual Meeting; Boston, MA, USA; Oct 2011. Available at: https://idsa. confex. com/idsa/2011/webprogram/Paper31075.html.
78. Haffizulla J, HartMan A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, pha- se 2b/3 trial. Lancet Infect Dis. 2014;14:609-18.
79. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;S1473-3099(20):30141-9.
80. Kraft CS, Hewlett AL, Koepsell S, et al; Nebraska Biocontainment Unit and the Emory Se- rious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61(4):496-502. 81. van Griensven J, Edwards T, de Lamballerie X, et al; Ebola-Tx Consortium. Evaluation of
convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33-42. 82. Florescu DF, Kalil AC, Hewlett AL, et al. Administration of brincidofovir and convalescent
plasma in a patient with Ebola virus disease. Clin Infect Dis. 2015;61(6):969-973.
83. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450-1451.
84. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in pa- tients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-456.
85. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020. Mar 27. doi: 10.1001/jama.2020.4783.
86. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 88 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.
87. Tang N, Li D, Wang X, Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7.
88. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mor- tality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 Mar 27. doi: 10.1111/jth.14817.
89. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 pa- tients. 2020. medRxiv: 2020.2002.2029.20029520.
90. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50:552-62. 91. Geng Z, Yu Y, Hu S, et al. Tocilizumab and the risk of respiratory adverse events in patients
with rheumatoid arthritis: a systematic review and meta-analysis of randomised control- led trials. Clinical and Experimental Rheumatology. 2019;37:318-23.
92. Mathurin KS, Martens GW, Kornfeld H and Welsh RM. CD4 T-cell-mediated heterologous immunity between Mycobacteria and Poxviruses. J Virol. 2009;83:3528-39.
93. Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune me- mory in health and disease. Science. 2016;352(6284):aaf1098.
94. Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of bcg vaccination on both heterologous th1/th17 responses and innate trained immunity. J Innate Immun. 2014;6:152-8. 95. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in
Guinea-Bissau, West Africa. BMJ. 2000;321:1435-39.
96. Miller A, Reandelar MJ, Fasciglione K, et al. Correlation between universal BCG vaccina- tion policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020.03.24.20042937. doi: https://doi.org/10.1101/2020.03.24.20042937.
97. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a commu- nity outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-72.
98. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-9.
99. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382:970-1.
100. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmis- sion potential of COVID 19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020. Available at: https://doi.org/10.1016/S0140 6736(20)30360 3. 101. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with
severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191:292-7.
102. Lam CM, Wong SF, Leung TN, et al. A case controlled study comparing clinical course and outcomes of pregnant and non pregnant women with severe acute respiratory syndro- me. BJOG. 2004;111:771-4.
103. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019- nCoV pneumonia. Transl Pediatr. 2020. doi: 10.21037/tp.2020.02.06.
104. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020. Available at: https://doi.org/ 10.1016/S0140 6736(20)30211 7.
105. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus infected pneumonia. N Engl J Med. 2020.
106. Cui Y, Tian M, Huang D, et al. A 55-day-old female infant infected with COVID 19: presen- ting with pneumonia, liver injury, and heart damage. J Infect Dis. 2020 Mar 17. pii: jiaa113. doi: 10.1093/infdis/jiaa113.
107. Cai J, Xu J, Lin D, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020 Feb 28. pii: ciaa198. doi: 10.1093/cid/ciaa198. 108. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in children in early January 2020 in
Wuhan, China. N Engl J Med. 2020 Mar 12. doi: 10.1056/NEJMc2003717.
109. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/ jama.2020.2648.
110. KCDC. Updates on COVID-19 in Korea. March 14, 2020. Available at: https://www.cdc.go.kr/ board/board.es?mid=a30402000000&bid=0030. Accessed on March 14 2020.
111. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coro- navirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lan- cet Infect Dis. 2020. Mar 25. Available at: https://doi.org/10.1016/S1473-3099(20)30198-5. 112. Fang Y, Zhang H, Xie J et al (2020) Sensitivity of chest CT for COVID-19: comparison to
RT-PCR. Radiology. Available at: https://doi.org/10. 1148/radiol.2020200432.
113. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697-722.
114. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020. Available at: https:// doi.org/10.1007/s00330-020-06731-x.
115. Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020. Available at: https://doi.org/10.1148/radiol. 2020200274.
116. Wu J, Wu X, Zeng W, et al. Chest CT findings in patients with corona virus disease 2019 and its relationship with clinical features. Invest Radiol. 2020. Available at: https://doi. org/10.1097/RLI.0000000000000670.
117. Kunhua Li JW, Wu F, Guo D, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol. 2020. Available at: https://doi. org/10.1097/RLI. 0000000000000672.
118. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respi- ratory distress syndrome. Lancet Respir Med. 2020. Available at: https://doi.org/10.1016/ S2213-2600(20)30076-X.
119. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020. Available at: https://doi. org/10.1148/radiol. 2020200370.
120. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneu- monia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020. Available at: https:// doi.org/10.1016/S1473-3099(20)30086-4.
121. Wong K, Antonio GE, Hui DS, et al. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology. 2003;228:395-400. 122. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (CO-
VID-19): relationship to duration of infection. Radiology. 2020. Available at: https://doi. org/10.1148/radiol.2020200463.
123. Kunhua Li JW, Wu F, Guo D, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol. 2020. Available at: https://doi.